Literature DB >> 12591956

Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine.

S Iuchi1, G Hoffner, P Verbeke, P Djian, H Green.   

Abstract

Neurological diseases resulting from proteins containing expanded polyglutamine (polyQ) are characteristically associated with insoluble neuronal inclusions, usually intranuclear, and neuronal death. We describe here oligomeric and polymeric aggregates formed in cells by expanded polyQ. These aggregates are not dissociated by concentrated formic acid, an extremely effective solvent for otherwise insoluble proteins. Perinuclear inclusions formed in cultured cells by expanded polyQ can be completely dissolved in concentrated formic acid, but a soluble protein oligomer containing the expanded polyQ and released by the formic acid is not dissociated to monomer. In Huntington's disease, a formic acid-resistant oligomer is present in cerebral cortex, but not in cerebellum. Cortical nuclei contain a polymeric aggregate of expanded polyQ that is insoluble in formic acid, does not enter polyacrylamide gels, but is retained on filters. This finding shows that the process of polymerization is more advanced in the cerebral cortex than in cultured cells. The resistance of oligomer and polymer to formic acid suggests the participation of covalent bonds in their stabilization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591956      PMCID: PMC151354          DOI: 10.1073/pnas.0437660100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  The expanded CAG repeat associated with juvenile Huntington disease shows a common origin of most or all neurons and glia in human cerebrum.

Authors:  P Kahlem; P Djian
Journal:  Neurosci Lett       Date:  2000-06-09       Impact factor: 3.046

2.  Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases?

Authors:  A J Cooper; K F Sheu; J R Burke; O Onodera; W J Strittmatter; A D Roses; J P Blass
Journal:  J Neurochem       Date:  1997-07       Impact factor: 5.372

3.  Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch.

Authors:  S Igarashi; R Koide; T Shimohata; M Yamada; Y Hayashi; H Takano; H Date; M Oyake; T Sato; A Sato; S Egawa; T Ikeuchi; H Tanaka; R Nakano; K Tanaka; I Hozumi; T Inuzuka; H Takahashi; S Tsuji
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

Review 4.  Tissue transglutaminase: a possible role in neurodegenerative diseases.

Authors:  M Lesort; J Tucholski; M L Miller; G V Johnson
Journal:  Prog Neurobiol       Date:  2000-08       Impact factor: 11.685

5.  Distinct nuclear localization and activity of tissue transglutaminase.

Authors:  M Lesort; K Attanavanich; J Zhang; G V Johnson
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

6.  Expansion of mouse involucrin by intra-allelic repeat addition.

Authors:  B Delhomme; P Djian
Journal:  Gene       Date:  2000-07-11       Impact factor: 3.688

Review 7.  Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease.

Authors:  J F Gusella; M E MacDonald
Journal:  Nat Rev Neurosci       Date:  2000-11       Impact factor: 34.870

8.  Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.

Authors:  A J Cooper; J Wang; R Pasternack; H L Fuchsbauer; R K Sheu; J P Blass
Journal:  Dev Neurosci       Date:  2000 Sep-Dec       Impact factor: 2.984

9.  Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: applying to quantification of protein components of the aggregates.

Authors:  N Hazeki; T Tukamoto; J Goto; I Kanazawa
Journal:  Biochem Biophys Res Commun       Date:  2000-10-22       Impact factor: 3.575

10.  Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases.

Authors:  V Gentile; C Sepe; M Calvani; M A Melone; R Cotrufo; A J Cooper; J P Blass; G Peluso
Journal:  Arch Biochem Biophys       Date:  1998-04-15       Impact factor: 4.013

View more
  20 in total

1.  Novel mutations that enhance or repress the aggregation potential of SOD1.

Authors:  Uma Krishnan; Marjatta Son; Bhagya Rajendran; Jeffrey L Elliott
Journal:  Mol Cell Biochem       Date:  2006-04-01       Impact factor: 3.396

2.  Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 pathogenesis.

Authors:  D R D'Souza; J Wei; Q Shao; M D Hebert; S H Subramony; P J S Vig
Journal:  Neurosci Lett       Date:  2006-10-11       Impact factor: 3.046

Review 3.  Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?

Authors:  Guylaine Hoffner; Philippe Djian
Journal:  Mol Neurobiol       Date:  2014-10-22       Impact factor: 5.590

4.  Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo.

Authors:  Robert O'Brien; Francesco DeGiacomo; Jennifer Holcomb; Akilah Bonner; Karen L Ring; Ningzhe Zhang; Khan Zafar; Andreas Weiss; Brenda Lager; Birgit Schilling; Bradford W Gibson; Sylvia Chen; Seung Kwak; Lisa M Ellerby
Journal:  J Biol Chem       Date:  2015-05-29       Impact factor: 5.157

5.  Structure of Membrane-Bound Huntingtin Exon 1 Reveals Membrane Interaction and Aggregation Mechanisms.

Authors:  Meixin Tao; Nitin K Pandey; Ryan Barnes; Songi Han; Ralf Langen
Journal:  Structure       Date:  2019-08-26       Impact factor: 5.006

Review 6.  Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Authors:  Guylaine Hoffner; Sylvie Souès; Philippe Djian
Journal:  Prion       Date:  2007 Jan-Mar       Impact factor: 3.931

Review 7.  A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules.

Authors:  Motomasa Tanaka; Yoko Machida; Nobuyuki Nukina
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

8.  PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.

Authors:  Na-Li Jia; Er-Kang Fei; Zheng Ying; Hong-Feng Wang; Guang-Hui Wang
Journal:  Neurosci Bull       Date:  2008-08       Impact factor: 5.203

9.  Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease.

Authors:  Jennifer L Wacker; Shao-Yi Huang; Andrew D Steele; Rebecca Aron; Gregor P Lotz; QuangVu Nguyen; Flaviano Giorgini; Erik D Roberson; Susan Lindquist; Eliezer Masliah; Paul J Muchowski
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

10.  Mechanism of cis-inhibition of polyQ fibrillation by polyP: PPII oligomers and the hydrophobic effect.

Authors:  Gregory D Darnell; JohnMark Derryberry; Josh W Kurutz; Stephen C Meredith
Journal:  Biophys J       Date:  2009-10-21       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.